| Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series |
|
Annals of Hematology |
Aplastic Anemia |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| How I Treat Paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
|
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
|
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
